Amazon Biotech, immunology clinic to conduct phase 1/2 study of AMZ0026 in HIV

By Lisa Kerner

Charlotte, N.C., July 17 - Amazon Biotech, Inc. signed an interim letter of agreement with the Immunology Clinic of New York to conduct a phase 1/2 randomized, double-blind, placebo-controlled study to test the safety and efficacy of its botanical drug product AMZ0026 in pre-symptomatic HIV-positive patients.

Arthur Englard of the Immunological Disease Clinic will serve as principal investigator.

Study subjects will be enrolled through the Immunology Clinic. However, Amazon is also negotiating with other potential investigative sites to participate in the study.

Amazon is a natural plant pharmaceutical company based in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.